Overview of cost-effectiveness analysis

11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...

Read more →

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

7 March 2019 - To make medicines more affordable, President Trump insists that “foreign freeloading” must end. ...

Read more →

Evaluating Canadians’ values for drug coverage decision making

2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Future unrelated medical costs need to be considered in cost effectiveness analysis

5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...

Read more →

Economic analysis falls short when it comes to medicines’ value

26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...

Read more →

When biotechs get breakthrough therapy status, Mr. Market yawns

23 February 2019 - As a biotech consultant, I’ve heard many CEO’s tell me that a “drumbeat of news” is ...

Read more →

Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?

21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...

Read more →

Determining value in health technology assessment: stay the course or tack away?

15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...

Read more →

How procurement judges the value of medical technologies: a review of health care tenders

8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...

Read more →

Cigna eclipses 50% in value-based care pay to providers

7 February 2019 - Cigna says it’s paying more than half of its reimbursements to medical care providers in its ...

Read more →

Discrete choice experiments in health economics: past, present and future

23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health.  ...

Read more →

ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures

23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...

Read more →

Will price be a barrier to new cancer immunotherapy?

19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...

Read more →

ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence

17 January 2019 - Public comments on draft protocol will be accepted through 13 February 2019. ...

Read more →